In conclusion, we constructed the chimeric peptide, B28Bn(6–14), for the purpose of evaluating the ability to specifically deliver a cytotoxic peptide, B28, to tumor cells by using Bn(6–14) as the vehicle. Here, MIS18A is linked to neoplasm.